As shown in Figure 5A-D, LOXL4 was the direct target of miR-29b and miR-30d, and inhibition of EZH2 reduced LOXL4 expression in breast cancer cells (Figure 1C-E; Figure S2). Here, EZH2 is linked to breast carcinoma.